Abstract
Background: Pharmacokinetics (PK), pharmacodynamics and optimal dosing of vancomycin in obese children is not known. Higher trough levels of vancomycin may improve outcomes. This prospective study evaluated the appropriateness of twice-daily regimen for the adherence to guidelines, among obese and non obese children.
Methods: Children receiving vancomycin, (20 mg/kg BID) were included. Patients were divided into 3 groups. Adequacy was defined as trough level ≥ 10mg/L and AUC/MIC > 400. An alternative-dosing regimen was calculated based on individual PK parameters.
Results: Seventy-seven pairs (trough, peak) were taken from 51 children. Mean trough level was 3.36±2.58, only 3% fell in therapeutic range, no statistical difference was observed between obese, normal weight or underweight groups. One child had an AUC/MIC > 400. All children recovered.
Conclusion: PK properties of all weight groups were similar. More frequent and higher doses are needed to achieve the goals of current guidelines.
Keywords: Guidelines, obesity, pediatric dosing, pharmacokinetics, trough levels, vancomycin, antimicrobials, antifungals, invasive, bacterial meningitis
Current Drug Safety
Title:Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Volume: 7 Issue: 5
Author(s): Laila Nassar, Salim Hadad, Aharon Gefen, Yael Shachor-Meyouhas, Tatiana Mashiach, Norberto Krivoy and Imad Kassis
Affiliation:
Keywords: Guidelines, obesity, pediatric dosing, pharmacokinetics, trough levels, vancomycin, antimicrobials, antifungals, invasive, bacterial meningitis
Abstract: Background: Pharmacokinetics (PK), pharmacodynamics and optimal dosing of vancomycin in obese children is not known. Higher trough levels of vancomycin may improve outcomes. This prospective study evaluated the appropriateness of twice-daily regimen for the adherence to guidelines, among obese and non obese children.
Methods: Children receiving vancomycin, (20 mg/kg BID) were included. Patients were divided into 3 groups. Adequacy was defined as trough level ≥ 10mg/L and AUC/MIC > 400. An alternative-dosing regimen was calculated based on individual PK parameters.
Results: Seventy-seven pairs (trough, peak) were taken from 51 children. Mean trough level was 3.36±2.58, only 3% fell in therapeutic range, no statistical difference was observed between obese, normal weight or underweight groups. One child had an AUC/MIC > 400. All children recovered.
Conclusion: PK properties of all weight groups were similar. More frequent and higher doses are needed to achieve the goals of current guidelines.
Export Options
About this article
Cite this article as:
Nassar Laila, Hadad Salim, Gefen Aharon, Shachor-Meyouhas Yael, Mashiach Tatiana, Krivoy Norberto and Kassis Imad, Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050009
DOI https://dx.doi.org/10.2174/1574886311207050009 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lantibiotic Production by Pathogenic Microorganisms
Current Protein & Peptide Science Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology Proteomics Analysis: A Powerful Tool to Identify Proteome Phenotype and Proteome Signature in Enterococcus faecalis
Current Proteomics Preparation and Characterization of Chitosan-Based Spray-Dried Microparticles for the Delivery of Clindamycin Phosphate to Periodontal Pockets
Current Drug Delivery Kingella kingae: A Pediatric Pathogen of Increasing Importance
Current Pediatric Reviews <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism COVID-19: How Nuclear Medicine Can Provide A Differential Diagnosis In A Very Dubious Case
Coronaviruses Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Waste Material of Propolis as a Film Forming Agent Intended to Modify the Metronidazole Release: Preparation and Characterization
Current Drug Delivery Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Current Pharmaceutical Design Coarctation of the Aorta - The Current State of Surgical and Transcatheter Therapies
Current Cardiology Reviews Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Enterococcal Cytolysin: A Novel Two Component Peptide System that Serves as a Bacterial Defense Against Eukaryotic and Prokaryotic Cells
Current Protein & Peptide Science 3-(1-Adamantylthio)-4-Phenylpyridine as a Potential Therapeutic for Methicillin-Resistant Staphylococcus aureus
Letters in Drug Design & Discovery Antimicrobial Precious-Metal Nanoparticles and their Use in Novel Materials
Recent Patents on Food, Nutrition & Agriculture Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Driving Forces of Mechanisms Regulating Oxacillin-Resistance Phenotypes of MRSA: Truly Oxacillin-Susceptible mecA-Positive Staphylococcus aureus Clinical Isolates also Exist
Current Pharmaceutical Design